CHRS - What's Going On With Coherus BioSciences Stock? | Benzinga
Coherus BioSciences, Inc. (NASDAQ: CHRS) shares are trading higher Monday after the company announced the FDA-approval of Loqtorzi in all lines of treatment for recurrent or metastatic nasopharyngeal carcinoma on Friday.
The Details:
On Friday, Coherus announced the FDA-approval of Loqtorzi making it the first and only FDA-apporved treatment for nasopharyngeal carcinoma.
"Loqtorzi's first approval is a pivotal event for Coherus as an ...